BRAF V600E-specific immunohistochemistry reveals low mutation rates in
- This topic has 1 reply, 2 voices, and was last updated 10 years, 7 months ago by
.
-
Posts
-
Gene mutation tests are one important tool in identifying possible treatment plans. Some medical centers include this test automatically, others do not. Patients should bring this to the attention of the physician.
Hugs,
MarionBRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
http://www.ncbi.nlm.nih.gov/pubmed/24309328
“In addition, we demonstrate that VE1 immunohistochemistry is a feasible approach to routinely screen for BRAF V600E mutation in biliary tract cancer patients, thereby facilitating the detection of rare patients who may benefit from BRAF mutation-targeted therapies.Modern Pathology advance online publication, 6 December 2013; doi:10.1038/modpathol.2013.206.”
- The forum ‘New Developments’ is closed to new topics and replies.